April 19, 2024

AI speeds up drug design for Parkinson’s ten-fold

The researchers, from the University of Cambridge, designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s.
The team used machine learning techniques to quickly screen a chemical library containing millions of entries, and identified five highly potent compounds for further investigation

https://www.cam.ac.uk/research/news/ai-speeds-up-drug-design-for-parkinsons-ten-fold?

RegulatingAI, a non-profit organization, is dedicated to establishing a platform for grassroots advocacy concerning artificial intelligence (AI) regulation. We serve as a bridge connecting AI experts, researchers, corporations, NGOs, academicians, students, and enthusiasts. RegulatingAI is committed to harnessing the power of shared knowledge to construct a responsible and ethical AI ecosystem.